From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...

Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...

Medical University of South Carolina scientists have uncovered a link between the innate immune system and cognitive problems ...

Advancing investigational pre-clinical research of APL-9099 3, a potential one-time neonatal Fc receptor (FcRn) treatment ...

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

If you're living with IgA nephropathy (IgAN), you know the weight it carries—the constant worry about your kidneys, the fatigue from proteinuria, and the fear of progressing to dialysis or a ...

Long Island acupuncture clinic expands services with AcuNova Acupuncture, a specialized approach designed to support ...

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease ...

OMER wins FDA approval for YARTEMLEA, the first TA-TMA therapy, marking its first commercial product and a shift to revenue generation.

Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...